The FSA and FSS authorization of a standardized tetrahydrocurcuminoids ingredient for use in food supplements expands the market access case for a curcumin derivative with a distinct stability and bioavailability profile.
Voluntary pledges from accreditors and medical schools to increase nutrition education may gradually shift how physicians engage with diet-based and supplement interventions.
The development underscores continued innovation in plant-based sweetener development and regulatory review.
A new PLT Health Solutions-Alethios collaboration focused on decentralized clinical research reflects growing demand among nutraceutical manufacturers for product-specific evidence.
New clinical findings involving Lactiplantibacillus plantarum 299v reflect growing interest in population-specific probiotic validation and microbiome research across Asian markets.
New funding and recent FDA approval activity are highlighting a growing industry interest in fermentation-derived natural colors.
The Dietary Supplements Access Act proposes expanding tax-advantaged healthcare accounts to include eligible supplements, reflecting growing attention on preventive wellness and consumer-directed health spending.
The Food and Drug Administration has formalized a new post-market assessment process for chemicals used in food and simultaneously opened reassessments of butylated hydroxytoluene and azodicarbonamide.
Companies must understand California Senate Bill 343, aka the Truth in Recycling Law, to meet compliance requirements by the October 4, 2026, effective date.
Food and Drug Administration Commissioner Marty Makary resigned from the agency, with FDA Deputy Commissioner for Food Kyle Diamantas acting as commissioner until a replacement is confirmed.
The US Food and Drug Administration reported mostly low or undetectable contaminants in infant formula, while signaling continued oversight and future action.
The trade association urges FDA to formalize flexible labeling practices, arguing that current ambiguity around DSHEA disclaimer placement is driving litigation risk and regulatory uncertainty.
With a positive EFSA opinion in hand, Nutriearth highlights a bioactive vitamin D3 oil and functional powder designed for improved absorption, lower dosing, and sustainable fortification strategies at Vitafoods Europe.
Associations in the natural products space argue that FDA’s interpretation of “dietary substance” is too narrow, potentially limiting innovation, safety oversight, and market access for emerging ingredients.
Live from SupplySide Connect, Megan Olsen, the SVP and general counsel for the CRN, discusses the FDA public meeting on dietary ingredients, the NDI vs. GRAS pathway, and the need for a clear, modern regulatory scope.
Live from SupplySide Connect, Megan Olsen, the SVP and general counsel for the CRN highlights growing concerns around DSHEA’s drug preclusion provision, underscoring the need for industry alignment and legislative reform in order to enable industry innovation.
Nutritional Outlook offers a practical guide for industry professionals on multivitamin efficacy, formulation trends, and regulatory considerations.
At SupplySide Connect New Jersey, Megan Olsen, SVP and general counsel of CRN, explains the organization's recent petition to the US Supreme Court to review a recent New York State law regarding supplements violates free speech.
New legislation introduced by Rep. Maxine Dexter aims to establish a federal product registry, drawing mixed reactions from leading industry organizations over implementation and impact.
At SupplySide Connect New Jersey, Karen Howard, the Organic & Natural Health Association’s CEO and executive director, discusses shifting industry strategy away from fragmented lobbying toward unified, consumer-focused education to drive meaningful regulatory and public health outcomes.
In a sit down with Nutritional Outlook, Brightseed’s Lee Chae explains how the company’s branded platform leverages artificial intelligence and structured biological data to accelerate ingredient discovery, strengthen substantiation, and reduce risk across nutraceutical product development.
Regulatory approval from Brazil’s health authority opens the door for Benicaros to enter a fast-growing supplement market, reinforcing global momentum for clinically validated, sustainable gut health ingredients.
New regulatory clearance for soy protein highlights growing demand for clinically substantiated, plant-based ingredients targeting cardiovascular health.
In the second part of this interview, Todd Harrison, Co-Chair of the FDA Group at Venable LLP, discusses how the FDA and the industry handle novel ingredients in functional foods.
In the first part of this interview, Todd Harrison, Co-Chair of the FDA Group at Venable LLP, shares insights into regulatory methods, GRAS notices, and nutrition facts labeling surrounding the lawsuit against David Protein.
The trade association is challenging speech-based restrictions on supplement sales to minors, raising broader questions about First Amendment protections and regulatory precedent in the nutraceutical industry.
Combining clinically studied ingredients with enhanced bioavailability, at Natural Products Expo West, Asha Ramesh, Sabinsa’s CEO – Americas, highlights the growing importance of safety data, regulatory compliance, and full documentation as brands navigate increasing scrutiny in supplement development.
From stress and cognitive support to formulation challenges and regulatory considerations, this FAQ explores the science and market forces shaping ashwagandha’s role in modern nutraceuticals.
What are the broader implications of the recent lawsuit against David Protein bars and food science, regulation, and consumer perspective on novel functional ingredients?
The lawsuit alleges the actual fat and calorie content of its protein bars is higher than stated on the labels, and the company defends its labeling accuracy, citing methods for determining nutrient content for non-bioavailable ingredients, such as its fat substitute, EPG.
